Skip to content
Screener

Ligand Pharmaceuticals LGND Other — Total revenues and income

Other product segments

Filspari
$13.57M+106%
Captisol
$7.98M
Kyprolis
$7.04M
Qarziba
$6.15M+4.5%
Evomela
$5.94M-31.5%
Rylaze
$3.81M+3.7%
Ohtuvayre
$3.55M
Ohtuvayre inventors
$3.29M
Contract revenue
$2.68M
Capvaxive
$2.32M
Teriparatide injection
$2.03M+19.2%
Vaxneuvance
$1.35M-48.9%

Similar metrics at other companies

Quanterix Corporation logo
QTRXService and other revenue — Total revenues
$10.38M+17.6%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%
ImmunityBio, Inc. logo
IBRXOther revenues — Total Revenue
$39K+388%
FIP
FIPOther revenue — Total revenues
$1.13M+112,900%
Red Robin Gourmet Burgers logo
RRGBOther revenue — Total revenues
$2.23M+8.5%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemThree months ended / June 30, 2026Three months ended / June 30, 2025Six months ended / June 30, 2026Six months ended / June 30, 2025
Capvaxive2,3162,2504,2853,135
Vaxneuvance1,3512,6432,9613,928
Teriparatide injection1,4702,2982,7913,489
Other4,2692,5648,0306,235
Revenue from intangible royalty assets37,36230,08470,29351,671
Qarziba6,1505,88512,44911,327
Ohtuvayre inventors3,2946,341
Other1,2264281,907888

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's other — total revenues and income?
Ligand Pharmaceuticals (LGND) reported other — total revenues and income of $4.27M in Q2 2026.
How has Ligand Pharmaceuticals's other — total revenues and income changed year-over-year?
Ligand Pharmaceuticals's other — total revenues and income increased by 66.5% year-over-year, from $2.56M to $4.27M.
What does other — total revenues and income mean?
This metric represents the aggregate financial inflows derived from royalty-based intangible assets and miscellaneous secondary business activities within the 'Other' segment. It captures revenue streams that fall outside of primary core operations, reflecting the monetization of intellectual property and ancillary service agreements. Monitoring this helps investors assess the contribution of non-core assets to the company's overall financial performance.

Ask your AI about Ligand Pharmaceuticals's other — total revenues and income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude